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Abstract
Background
Methotrexate (MTX) is an important anti-folate agent in pediatric acute lymphoblastic leuke-
mia (ALL) treatment. Folinic acid rescue therapy (Leucovorin) is administered after MTX to
reduce toxicity. Previous studies hypothesized that Leucovorin could ‘rescue’ both normal
healthy cells and leukemic blasts from cell death. We assessed whether Leucovorin is able
to restore red blood cell folate levels after MTX.
Methods
We prospectively determined erythrocyte folate levels (5-methyltetrahydrofolate (THF) and
non-methyl THF) and serum folate levels in 67 children with ALL before start (T0) and after
stop (T1) of HD-MTX and Leucovorin courses.
Results
Erythrocyte folate levels increased between T0 and T1 (mean ± SD: 416.7 ± 145.5 nmol/L
and 641.2 ± 196.3 nmol/L respectively, p<0.001). This was due to an increase in 5-methyl
THF levels (mean increase: 217.7 ± 209.5 nmol/L, p<0.001), whereas non-methyl THF lev-
els did not change (median increase: 0.6 nmol/L [-9.9–11.1], p = 0.676). Serum folate levels
increased between T0 and T1 (median increase: 29.2 nmol/L [32.9–74.0], p<0.001). Results
were not significantly affected by age, sex, ALL immunophenotype and MTHFR c.677C>T
genotype.
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Conclusion
Intracellular folate levels accumulate after HD-MTX and Leucovorin therapy in children with
ALL, suggesting that Leucovorin restores the intracellular folate pool. Future studies are
necessary to assess concomitant lower uptake of MTX.
Introduction
High-dose methotrexate (HD-MTX) is an important component of pediatric acute lympho-
blastic leukemia (ALL) treatment. [1–3] Methotrexate is a cytotoxic agent that depletes intra-
cellular reduced folate levels by inhibiting the enzymes Dihydrofolate Reductase (DHFR) and
Thymidylate Synthase (TYMS) (Fig 1). [4–6] MTX thereby inhibits DNA- and RNA synthesis.
[4–6] After HD-MTX infusions, folinic acid rescue therapy (Leucovorin) is administered to
reduce toxic side effects of therapy. [7]
Previous studies showed that red blood cell folate levels have been low in patients treated with
only MTX without Leucovorin. [8–10] Leucovorin and MTX are structural analogues and could
therefore compete for cellular transport-, polyglutamylation-, and enzyme-binding (DHFR/TS)
mechanisms. [11, 12] As a reduced folate, Leucovorin could also bypass the enzyme DHFR dur-
ing consecutive HD-MTX and LV courses, thereby restoring purine- and pyrimidine- synthesis.
It has been hypothesized that Leucovorin restores cellular folate levels after MTX (Fig 1). This
phenomenon has been referred to as the folate ‘overrescue’ principle, where not only healthy
cells, but also tumor cells are ‘rescued’ from cell death due to Leucovorin after HD-MTX.
Both in pediatric ALL studies [13–16] as in rheumathoid arthritis studies [17, 18] results sug-
gested that Leucovorin rescue therapy decreases toxicity rates, but showed an increased risk of
relapse in ALL and decreased treatment efficacy in RA. In contrast, others have successfully
introduced early LV rescue in individualized doses after MTX in treatment protocols with high
event-free survival rates. [19–21] In addition, previous studies failed to detect correlations
between red blood cell (RBC) MTX and folate levels measured at end of intensification therapy
and throughout maintenance therapy in relation to complete continuous remission and event-
free survival rates. [8, 21] These contradictory study results emphasize the difficulties still
encountered in understanding the impact in Leucovorin and MTX on pediatric ALL treatment
outcome. This is undesirable as both treatment efficacy and toxicity are affected by the possible
competition between MTX and Leucovorin. Until now, no studies have assessed the effect of 4x
consecutive HD-MTX (5000 mg/m2/dose) and Leucovorin on RBC folate levels.
Different folate vitamers are involved in intracellular folate metabolism. Intracellular folate
levels can be divided into two pools: the 1) 5-methyl tetrahydrofolate (THF) pool serving the
methylation cycle and the 2) non-methyl THF pool serving the DNA/RNA biosynthesis cycle
(Fig 1). In plasma, the main folate isoform that accumulates after Leucovorin (folinic acid;
5-formyl THF) infusion is 5-methyl tetrahydrofolate (5-methyl THF) (Fig 1). [22–24] In
mature erythrocytes, which are regarded as the best intracellular reflection of the whole-body
folate status over the past three months, 5-methyl THF is the largest pool. [25] Previous studies
showed that after intravenous and oral administration of Leucovorin, 5-formylTHF, THF and
5,10-methylTHF had a short T1/2 of 30 minutes after administration, after which 5-methylTHF
accumulated. [24, 26–28] In addition, homocysteine and vitamin B12 are important biomark-
ers of intracellular one-carbon metabolism (Fig 1). Homocysteine reflects changes in the one-
carbon metabolism due to disturbances of folate- and vitamin B12 levels and increases in
response to MTX therapy. [29, 30] Vitamin B12 is involved in one-carbon metabolism as co-
enzyme facilitating the re-methylation of homocysteine into methionine (Fig 1). [31]
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This study aims to determine whether serum and intracellular folate levels accumulate dur-
ing four consecutive HD-MTX and Leucovorin courses in children with ALL. In addition, we
studied homocysteine and vitamin B12 levels during HD-MTX and Leucovorin courses.
Results
Patient characteristics
In total, 67 children with ALL treated according to the Dutch Childhood Oncology Group ALL-
10 protocol (S1 Fig) were included in this study (Fig 2). The median age at diagnosis was 5.4
years (range 1.4–17.5). Thirty patients were female (45%), 48 patients were treated in the medium
risk group (72%) and 58 patients had a B-lineage ALL (87%). Thirty-two (48%) patients were car-
riers of the MTHFR 677 CC genotype, 24 (36%) patients of the MTHFR 677 CT genotype, 10
(15%) patients of the MTHFR 677 TT genotype and in 1 (1%) patient the genotype was missing.
Laboratory measurements before start (T0) and after stop (T1) of
HD-MTX treatment
Erythrocyte folate increased significantly between T0 and T1 (mean 224.4 ± 220.7 nmol/L)
(Table 1 + Fig 3). This increase was due to an increase in erythrocyte 5-methyl THF levels
(mean 217.7 ± 209.5 nmol/L), whereas erythrocyte non-methyl THF levels remained stable
(median 0.6 nmol/L [-9.9–11.1]) throughout treatment. Serum folate levels increased
Fig 1. Folate pathway. Overview of the folate pathway with separate folate isoforms and converting enzymes. Leucovorin (5-formyl THF) rescue therapy bypasses the
action of DHFR. SAM: S-adenosylmethionine; SAH: S-adenosylhomocysteine; DHF: dihydrofolate; THF: tetrahydrofolate; TS: thymidylate synthase; DHFR:
dihydrofolate reductase; MTHFD1: methylenetetrahydrofolate dehydrogenase 1; MTHFR: methylenetetrahydrofolate reductase; MTX: methotrexate; LV: Leucovorin.
https://doi.org/10.1371/journal.pone.0221591.g001
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significantly between T0 and T1 (median 29.2 nmol/L [19.3–57.4]), plasma homocysteine levels
decreased significantly (-2.5 ± 2.5 μmol/L), while serum vitamin B12 levels did not change
(median -4.9 pmol/L [-131.0–40.9], p = 0.134) (Table 1 + Fig 3). Due to the presence of extreme
outliers for the Delta T1 –T0, a sensitivity analysis with and without outliers was performed.
Results did not change after the sensitivity analysis (data not shown). No correlation between
erythrocyte folate levels at T0/T1 and erythrocyte MTX-PG1-5 at T1 existed (data not shown).
Covariates
In univariable analysis, ALL immunophenotype was significantly associated with the Delta T1
–T0 erythrocyte 5-methyl THF levels and the Delta T1 –T0 erythrocyte sum folate levels and
age was significantly associated with the Delta T1 –T0 plasma homocysteine levels (data not
shown). However, none of these confounders significantly affected the Delta T1 –T0 in a linear
regression model (Table 2).
One-carbon metabolism markers in relation to toxicity
Changes in erythrocyte- and plasma folate, plasma homocysteine and plasma vitamin B12 lev-
els between T0 and T1 were not significantly associated to the development of MTX-induced
oral mucositis NCI� grade 3 (Table 3).
Fig 2. Flowchart patient inclusion. Abbreviations: ALL, acute lymphoblastic leukemia; HD-MTX, high-dose
methotrexate; DCOG, Dutch Childhood Oncology Group; SNP, single-nucleotide polymorphism; n = number of
patients; � 1 patient had neurological damage before start HD-MTX treatment, 1 patients was transferred to another
hospital, 1 patient had an adjusted protocol due to a SPINKS mutation and 1 patient was initially treated otherwise due
to another diagnosis.
https://doi.org/10.1371/journal.pone.0221591.g002
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Discussion
In this study we assessed intracellular folate levels throughout HD-MTX and Leucovorin ther-
apy in children with ALL. We showed that intracellular 5-methyl THF levels increased during
high-dose MTX and Leucovorin therapy, suggesting that Leucovorin is able to restore the
intracellular folate pool.
In this study, we observed an increase in 5-methyl THF pool, whereas the non-methyl THF
pool did not change. It is likely that throughout the course of four HD-MTX and Leucovorin
courses in 57 days the non-methyl THF pool is largely reduced to 5-methyl THF. The increase
of folate levels observed in patients receiving MTX and Leucovorin is likely due to Leucovorin,
as previous studies showed low red blood cell folate levels in patients treated with MTX mono-
therapy. [8–10] Our findings are in line with findings of Holmboe et al (2012), who showed a
similar increase in erythrocyte folate levels in osteosarcoma patients receiving HD-MTX and
LV. [32] However, as we could not compare our data to patients that received a similar treat-
ment protocol with HD-MTX without Leucovorin, we could not exclude effects of other co-
medication such as 6-Mercaptopurine or nutritional factors.
In this study, we did not find an association between the change in folate metabolism mark-
ers and the development of oral mucositis NCI grade�3 throughout protocol M. However, in
this study design we only had folate metabolism markers at start and at the end of protocol M
and we could have missed effects throughout the four different HD-MTX courses.
Homocysteine is a sensitive biomarker of one-carbon / folate metabolism (Fig 1), that was
shown to be increased in plasma in response to MTX administration. [16, 33] This initial
increase in homocysteine levels was reversed after start of Leucovorin. [16] In line with these
previous results, plasma homocysteine levels in our study decreased after high-dose MTX and
Leucovorin therapy confirming that the intracellular folate pool was restored.
In recent years concerns have been raised about the possible adverse effects of excessive
folate intake in the field of folic acid food fortification due to the ‘methylfolate trap’. [34] This
Table 1. One-carbon metabolism metabolite levels at T0 and T1 (n = 67).
T0 (before start MTX) T1 (after stop MTX) Delta T1 –T0 p-value
Ery 5-methyl THF (nmol/L), mean ± SD 370.2 ± 149.3 587.8 ± 194.6 217.7 ± 209.5 <0.0001�
Ery Non-methyl THF (nmol/L), median (IQR) 27.0 (17.1–48.4) 30.4 (18.6–56.3) 0.6 (-9.9–11.1) 0.676
Ery Sum Folate Levela (nmol/L), mean ± SD 416.7 ± 145.5 641.2 ± 196.3 224.4 ± 220.7 <0.0001�
Plasma Homocysteine (μmol/L), mean ± SDb 7.8 ± 2.9 5.3 ± 1.2 -2.5 ± 2.5 <0.0001�
Serum Vitamin B12 (pmol/L), median (IQR) 345.6 (255.9–531.4) 363.2 (233.8–465.3) -4.9 (-131.0–40.9) 0.134
Serum Folate (nmol/L), median (IQR) 16.4 (11.5–24.3) 42.8 (32.9–74.0) 29.2 (19.3–57.4) <0.0001�
a sum 5-methylTHF + non-methylTHF
b In n = 2 patients homocysteine levels were missing.
�p-value < 0.05. Univariate analysis of changes of folate metabolism markers between T0 and T1 using a paired T test (normally distributed data; mean ± Standard
Deviation (SD)) or a Wilcoxon Singed Rank Test (skewed distributed data; median, Interquartile Range (IQR)).
Reference values in healthy population
Ery 5-methylTHF (nmol/L) median (range) 427.3 (92.5–1085.8)c
Ery non-methylTHF (nmol/L) median (range) 4.1 (0–786.2)c
Ery sum folate level (nmol/) median (range) 440.9 (170.3–1164.4)c
Plasma Homocysteine (μmol/L) reference interval 5.0–15.0d
Serum Vitamin B12 (pmol/L) reference interval 145–637d
Serum folate (nmol/L) reference interval 5–40dc
chttps://www.sciencedirect.com/science/article/pii/S0955286307000149?via%3Dihub
dAccording to reference values of our laboratory
https://doi.org/10.1371/journal.pone.0221591.t001
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‘methylfolate trap’ is based on the fact that the conversion of 5,10-methylene THF to 5-methyl
THF is irreversible (Fig 1). To maintain an intact folate cycle, 5-methyl THF can only be con-
verted to THF by the vitamin B12-dependent re-methylation of homocysteine to methionine.
If either folate levels are excessively high or if vitamin B12 levels are low, this could then lead to
‘trapping’ of 5-methyl THF with concomitant high levels of homocysteine and subsequently
the impairment of essential intracellular methylation and DNA / RNA synthesis processes.
[35, 36] In the setting of our study, patients received Leucovorin, which led to iatrogenic
increased intracellular folate levels. However, as homocysteine levels decreased during therapy
and vitamin B12 levels were within the normal range (>148 pmol/L), we did not find evidence
of the ‘methylfolate trap’.
We have demonstrated that intracellular folate levels increase upon HD-MTX and Leucov-
orin treatment in pediatric ALL-patients. It is of interest to assess the magnitude of this
increase in relation to intracellular folate levels found in healthy individuals. Compared with
healthy adults the median sum of the intracellular folate vitamers at T1 are increased, but the
majority of values are within the large normal range found in the healthy adult population
(median 440.0 nmol/L, range 170.3–1164.4]). [25] The large interindividual variability in
intracellular erythrocyte folate levels in our pediatric ALL patients are in line with the variabil-
ity reported in the healthy population and might be partly explained by pre-analytical condi-
tions, genetic variation in genes of folate transporters and metabolizing enzymes, such as the
MTHFR c.677 C>T genotype, as well as differences in dietary folate intake. [25]
Fig 3. One carbon metabolism metabolite levels before (T0) and after (T1) high-dose MTX therapy. One carbon
metabolism metabolite levels before (T0) and after (T1) of high-dose MTX therapy: erythrocyte 5-methyl THF (a,
p<0.0001), erythrocyte non-methyl THF (b, p = 0.676) sum erythrocyte folate isoforms (c, p<0.0001), serum folate (d,
p<0.0001), plasma homocysteine (d, p<0.0001), serum vitamin B12 (e, p = 0.134). The red lines depict the median
levels and the blue lines depict the 95% confidence interval.
https://doi.org/10.1371/journal.pone.0221591.g003
Table 2. Estimated linear regression coefficients with 95% confidence intervals.
β 95% CI
Ery 5-methyl THF (nmol/L)
Model 1 Delta Ery 5-methyl THF (nmol/L) T1 –T0Ery 5-methyl THF (nmol/L) T0 -0.63 (-0.95
–-0.32)
Model 2 Delta Ery 5-methyl THF (nmol/L) T1 –T0 Ery 5-methyl THF (nmol/L) T0
ALL immunophenotype
-0.59# (-0.92
–-0.26)
Ery Sum Folate Vitamers (nmol/L)
Model 1 Delta Ery Sum Folate Vitamers (nmol/L) T1 –T0 Ery Sum Folate Vitamers (nmol/L)
T0
-0.75 (-1.07
–-0.41)
Model 2 Delta Ery Sum Folate Vitamers (nmol/L) T1 –T0 Ery Sum Folate Vitamers (nmol/L)
T0ALL immunophenotype
-0.70# (-1.04
–-0.36)
Plasma Homocysteine (μmol/L)
Model 1 Delta Plasma Homocysteine (μmol/L) T1 –T0 Plasma Homocysteine (μmol/L) T0 -0.77 (-0.85
–-0.69)
Model 2 Delta Plasma Homocysteine (μmol/L) T1 –T0 Plasma Homocysteine (μmol/L)
T0Age
-0.83# (-0.91
–-0.74)
Possible confounders that were both significantly associated with T0 and delta T1-T0 were entered in model 2 to see
whether the β changed >10%; ALL immunophenotype was added to model 2 for Ery 5-methyl THF and Ery Sum
Folate vitamers and age for Plasma Homocysteine. β = regression coefficient, SE = Standard Error of β, 95%
CI = 95% Confidence Interval of β
#Change in β was <10%.
https://doi.org/10.1371/journal.pone.0221591.t002
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We showed that intracellular folate levels before start of the first HD-MTX (T0) course and
after stop of four HD-MTX (T1) courses were not correlated to intracellular MTX-PG1-5 after
stop of four HD-MTX (T1) courses in this study. This needs to be assessed in more detail in
future studies. Previous studies showed that side effects, such as oral mucositis, predominantly
occur during the first out of four HD-MTX courses. [37] It would be of value to assess intracel-
lular folate- and MTX levels more frequently throughout the treatment protocol as it could be
that competition for cellular transport mechanisms exists more early in the treatment
protocol.
In this study, we measured intracellular folate levels in erythrocytes. Erythrocytes are
expected to be a reflection of intracellular folate status of other cells such as leucocytes, as
erythroblasts take up folate and most of this pool is retained throughout its lifespan. However,
it would be of scientific value to determine folate levels in nuclear cells such as leucocytes, as
erythrocytes do not have a nucleus nor mitochondria and therefore no active formation of
DNA- or RNA structures. [38]
Strengths of this study are the prospective collection of samples and the erythrocyte folate
vitamer level measurements. A limitation is that we only measured folate levels before start of
HD-MTX therapy and after stop of HD-MTX therapy, whereas in future studies it would be
valuable to measure these levels more frequently throughout the treatment protocol.
In conclusion, intracellular folate levels accumulate during HD-MTX and Leucovorin ther-
apy in children with ALL with a concomitant decrease in plasma homocysteine levels. These
results support the hypothesis that Leucovorin restores the intracellular folate pool during
treatment with MTX. Future studies that determine whether intracellular folate levels are asso-
ciated with a decrease in intracellular MTX levels throughout the HD-MTX treatment protocol
Table 3. Delta one-carbon metabolism levels in relation to MTX-induced oral mucositis (n = 67).
Delta T1 –T0 n (%) nmol/L p-value p-value correcteda OR (95% CI)
5-methyl THF, median (IQR)
Mucositis–no 53 (79) 205.21 (103.9–414.0) 0.157 0.215 0.997 (0.993–1.002)
Mucositis—yes 14 (21) 40.6 (-9.1–287.9)
Non-methyl THF, median (IQR)
Mucositis–no 53 (79) 0.6 (-10.9–10.5) 0.974 0.864 0.999 (0.987–1.011)
Mucositis—yes 14 (21) -1.1 (-11.1–18.6)
Sum Folateb, median (IQR)
Mucositis–no 53 (79) 201.2 (96.9–411.0) 0.176 0.402 0.999 (0.995–1.002)
Mucositis—yes 14 (21) 129.1 (34.4–297.5)
Plasma Homocysteinec, median (IQR)
Mucositis–no 51 (78) -2.1 (-3.6 - -0.6) 0.737 0.085 0.509 (0.236–1.098)
Mucositis–yes 14 (22) -1.6 (-5.1 - -0.8)
Plasma Vitamin B12, median (IQR)
Mucositis–no 53 (79) -4.9 (-131.8–51.6) 0.554 0.866 1.000 (0.995–1.004)
Mucositis–yes 14 (21) 2.2 (-114.6–26.6)
Plasma Folic acid (nmol/L), median (IQR)
Mucositis–no 53 (79) 29.7 (21.5–57.4) 0.262 0.241 0.981 (0.951–1.013)
Mucositis–yes 14 (21) 23.4 (11.7–53.1)
a Delta variables corrected for value at T0, age and gender; 5-methylTHF / non-methylTHF pool corrected for age, gender and MTHFR C667T genotype
b sum 5-methylTHF + non-methylTHF.
c In n = 2 patients homocysteine levels were missing.
https://doi.org/10.1371/journal.pone.0221591.t003
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are of interest to assess whether competition between MTX and Leucovorin exists for cellular
transport mechanisms.
Methods
Patient selection
Pediatric ALL patients (1–19 years) treated with HD-MTX courses according to the standard and
medium risk arms of the Dutch Childhood Oncology Group ALL-10 protocol were eligible for
this study. [39] We obtained written informed consent from patients and their parents before
sample collection according to the Declaration of Helsinki. The study was approved by the Medi-
cal Ethical Committee Erasmus Medical Center (Erasmus MC, Rotterdam, The Netherlands,
MEC-2005-358). Children were diagnosed with ALL in the period between 2004 and 2012 in two
Dutch pediatric oncology centers (the Erasmus MC–Sophia Children’s Hospital in Rotterdam
and the University Medical Center Groningen (UMCG)–Beatrix Children’s Hospital in Gro-
ningen). We studied patients prospectively during protocol M (4x 5g/m2 high-dose MTX
courses). Detailed information on this protocol and cohort has been previously described. [37] In
short, four HD-MTX infusions were administered every two weeks at a dose of 5000 mg/m2 in
24 hours. Each MTX administration was combined with intrathecal triple chemotherapy in a
standard dose adjusted for age (8–12 mg MTX; 20–30 Cytosine Arabinoside; 8–12 mg Diadreson
F aquosum). Folinic acid rescue therapy (15 mg/m2/dose) was administered at 42, 48 and 54
hours after the start of MTX administration. Standard supportive care guidelines included hyper-
hydration (2.5–3.0 L/m2/day) and urine alkalinization using sodium bicarbonate (pH between
7.0–8.0). In addition, protocol M included oral 6-mercaptopurine (25 mg/m2 daily for 56 days).
Erythrocyte folate, serum folate, plasma homocysteine and serum vitamin
B12 measurements
Red blood cell pellets, serum and EDTA plasma samples were collected from the patients
before the start of protocol M (T0) and two weeks after discontinuation of protocol M (T1) for
measurement of erythrocyte folate levels (S1 Fig). All samples were stored at − 80 ˚C and ana-
lyzed collectively. Erythrocyte folate levels (non-methyl tetrahydrofolate (non-methyl THF)
pool; 5-methyl tetrahydrofolate (5-methyl THF) pool; folic acid pool) were measured using liq-
uid chromatography-tandem mass spectrometry as previously described. [40] The non-methyl
THF pool consists of the sum of THF, 5,10-methylene THF, 5,10-methenyl THF and 5- and
10-formyl THF (Fig 1). As folic acid concentrations were negligible (median 1.2; range 0.5–7.3
nmol/L), the sum of the total erythrocyte folate level was calculated by adding the non-methyl
THF and 5-methyl THF pools. Serum folate levels and serum vitamin B12 levels were mea-
sured using an electrochemiluminescence immunoassay (Modular E170, Roche, Almere, The
Netherlands). Plasma homocysteine levels were measured using liquid chromatography-tan-
dem mass spectrometry as previously described. [41] Samples of erythrocyte MTX-polygluta-
mates (MTX-PG1-5) were only collected at T1 and were measured as previously described. [42]
Statistical analysis
A Paired-Samples T-test (normally distributed variables; mean ± SD) and a Wilcoxon Signed
Rank test (skewed variables; median [interquartile range]) were used to compare mean or
median erythrocyte 5-methyl THF, erythrocyte non-methyl THF, erythrocyte sum folate,
serum folate, plasma homocysteine and serum vitamin B12 levels at T0 and T1 in univariate
analysis. A linear regression model was estimated to assess the effect of age at diagnosis, sex,
ALL immunophenotype and MTHFR c.677C>T genotype on the absolute changes in these
Intracellular folate during high-dose methotrexate in pediatric acute lymphoblastic leukemia
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folate metabolism markers between T0 and T1 (Delta T1 –T0), while correcting for the levels at
T0. A logistic regression model was estimated to assess the effect of the change in folate metabo-
lism markers between T0 and T1 (Delta T1-T0) in relation to the development of MTX-induced
oral mucositis NCI grade�3, while correcting for age at diagnosis, sex, ALL immunophenotype
and MTHFR c.677C>T genotype. Possible confounders were included in the linear regression
model when they had a p-value<0.20 in univariable analysis. Possible confounders that were
entered into the linear regression model were considered significant when they changed the β
> 10%. A Pearson correlation coefficient was calculated to assess the association between eryth-
rocyte non-methyl THF / erythrocyte 5 methyl THF / erythrocyte sum folate levels at T0 and T1
and erythrocyte MTX-PG1-5 (and subdivided in MTX-PG1-3 and MTX-PG4-5) at T1.
Supporting information
S1 Fig. Treatment protocol M—DCOG ALL10 protocol.
(TIF)
S1 File. Dataset.
(CSV)
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